Immunobiology of allogeneic hematopoietic stem cell transplantation

Lisbeth A. Welniak; Bruce R. Blazar; William J. Murphy

doi:10.1146/annurev.immunol.25.022106.141606

Immunobiology of allogeneic hematopoietic stem cell transplantation

Lisbeth A. Welniak, Bruce R. Blazar, William J. Murphy

Research output: Contribution to journal › Article › peer-review

413 Scopus citations

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) has evolved into an effective adoptive cellular immunotherapy for the treatment of a number of cancers. The immunobiology of allogeneic HSCT is unique in transplantation in that it involves potential immune recognition and attack between both donor and host. Much of the immunobiology of allogeneic HSCT has been gleaned from preclinical models and correlation with clinical observations. We review our current understanding of some of the issues that affect the success of this therapy, including host-versus-graft (HVG) reactions, graft-versus-host disease (GVHD), graft-versus-tumor (GVT) activity, and restoration of functional immunity to prevent transplant-related opportunistic infections. We also review new strategies to optimize the GVT and improve overall immune function while reducing GVHD and graft rejection.

Original language	English (US)
Pages (from-to)	139-170
Number of pages	32
Journal	Annual Review of Immunology
Volume	25
DOIs	https://doi.org/10.1146/annurev.immunol.25.022106.141606
State	Published - 2007

Keywords

Graft rejection
Graft-versus-host disease
Immune reconstitution

PubMed: MeSH publication types

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1146/annurev.immunol.25.022106.141606

Find It

Find It at U of M Libraries

Cite this

@article{7a81d0952fbe49ae8a45e6dc233bb470,

title = "Immunobiology of allogeneic hematopoietic stem cell transplantation",

abstract = "Allogeneic hematopoietic stem cell transplantation (HSCT) has evolved into an effective adoptive cellular immunotherapy for the treatment of a number of cancers. The immunobiology of allogeneic HSCT is unique in transplantation in that it involves potential immune recognition and attack between both donor and host. Much of the immunobiology of allogeneic HSCT has been gleaned from preclinical models and correlation with clinical observations. We review our current understanding of some of the issues that affect the success of this therapy, including host-versus-graft (HVG) reactions, graft-versus-host disease (GVHD), graft-versus-tumor (GVT) activity, and restoration of functional immunity to prevent transplant-related opportunistic infections. We also review new strategies to optimize the GVT and improve overall immune function while reducing GVHD and graft rejection.",

keywords = "Graft rejection, Graft-versus-host disease, Immune reconstitution",

author = "Welniak, {Lisbeth A.} and Blazar, {Bruce R.} and Murphy, {William J.}",

year = "2007",

doi = "10.1146/annurev.immunol.25.022106.141606",

language = "English (US)",

volume = "25",

pages = "139--170",

journal = "Annual Review of Immunology",

issn = "0732-0582",

publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Immunobiology of allogeneic hematopoietic stem cell transplantation

AU - Welniak, Lisbeth A.

AU - Blazar, Bruce R.

AU - Murphy, William J.

PY - 2007

Y1 - 2007

N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) has evolved into an effective adoptive cellular immunotherapy for the treatment of a number of cancers. The immunobiology of allogeneic HSCT is unique in transplantation in that it involves potential immune recognition and attack between both donor and host. Much of the immunobiology of allogeneic HSCT has been gleaned from preclinical models and correlation with clinical observations. We review our current understanding of some of the issues that affect the success of this therapy, including host-versus-graft (HVG) reactions, graft-versus-host disease (GVHD), graft-versus-tumor (GVT) activity, and restoration of functional immunity to prevent transplant-related opportunistic infections. We also review new strategies to optimize the GVT and improve overall immune function while reducing GVHD and graft rejection.

AB - Allogeneic hematopoietic stem cell transplantation (HSCT) has evolved into an effective adoptive cellular immunotherapy for the treatment of a number of cancers. The immunobiology of allogeneic HSCT is unique in transplantation in that it involves potential immune recognition and attack between both donor and host. Much of the immunobiology of allogeneic HSCT has been gleaned from preclinical models and correlation with clinical observations. We review our current understanding of some of the issues that affect the success of this therapy, including host-versus-graft (HVG) reactions, graft-versus-host disease (GVHD), graft-versus-tumor (GVT) activity, and restoration of functional immunity to prevent transplant-related opportunistic infections. We also review new strategies to optimize the GVT and improve overall immune function while reducing GVHD and graft rejection.

KW - Graft rejection

KW - Graft-versus-host disease

KW - Immune reconstitution

UR - http://www.scopus.com/inward/record.url?scp=34247867901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247867901&partnerID=8YFLogxK

U2 - 10.1146/annurev.immunol.25.022106.141606

DO - 10.1146/annurev.immunol.25.022106.141606

M3 - Article

C2 - 17129175

AN - SCOPUS:34247867901

SN - 0732-0582

VL - 25

SP - 139

EP - 170

JO - Annual Review of Immunology

JF - Annual Review of Immunology

ER -

Immunobiology of allogeneic hematopoietic stem cell transplantation

Abstract

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this